Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Now where did I put that comma?
Is it "Let's go eat Granny" or "Let's go eat, Granny"
I realise that it takes 20% of the time to get 80% of the objective done and 80% of the time to get the last 20% perfected. So I apologise for typos while we deliver triple digit percentage growth :-) And big companies are more interested in solving their problem, increasing their profits, than grammer, when you consider that the majority of our clients have English as their second language. Chill out, we are getting there.
@StuoftheToon, I mentioned on Twitter that most don't understand the amount of paperwork, licence and other associated safety issues Deepverge had to go through to own and manage containment level 3 laboratories. While others are waiting in a queue to access a handful of labs across the country, we have two private ones operating 24/7/365 on multiple dangerous pathogens. Also ensures reduced odours when testing sewage sludge for virus. One man muck is pure gold in the right (gloved) hands
@TPKart Thank you for your comment. There is a whole lot more behind that front page, which is only a holding page. The full extent of PR and copy is yet to come. Rest assured we have good people on this.
The reference to not following procedure on sale of shares requires clarification. All proper procedures were followed to the letter for the sale, including written notice and permission sought and received from the BOD, with notification to NOMAD. The oversight relates to 2018.
Sorry double post, but you asked...
@trillsg If you could recall the condition of Integumen when new management got involved in August 2018. It had no cash, short term debts of close to £3m and July payroll of the remaining 5 staff in Labskin had not been met. Private funding was provided by new management in travel, expenses and no salary, which is why we took shares. Until December, the entire exercise was more putting out fires, with paltry funding, and short term debt, totally hand to mouth.
In that time, a number of urgent crisis were encountered, which required immediate cash and so my wife provided private funding and this was supposed to have been paid back at the next placing of £750,000, which ended up being a Placing of £170,000 and subscription of £180,000, plus a rolling flexible facility from Cellulac. Debts to Cellulac were also supposed to be addressed from the Placing. However, shares were issued instead and Cellulac dealt with the debt to my wife with shares which was later paid back to Cellulac as advances made in the Loan Note (see RNS of the 1st November 2018).
So, Integumen did not issue shares to my wife, part of the payment of shares to Cellulac, was used to settle that small (£12,600) debt to my wife. That is why it was not shown up as a direct issue from Integumen.
On the second part, my wife, had not invested in MWG and did not gain 500% profit, like others, so she wished to participate in the Microsaic transformation, and used those shares to settle payment of £50,000 (plus her CGT on the profit from those shares).
I doubt if any single director of an AIM Company would be as open as that, and I don't begrudge her making a profit from helping to save Integumen (Deepverge) when nobody else would.
If you could recall the condition of Integumen when new management got involved in August 2018. It had no cash, short term debts of close to £3m and July payroll of the remaining 5 staff in Labskin had not been met. Private funding was provided by new management in travel, expenses and no salary, which is why we took shares. Until December, the entire exercise was more putting out fires, with paltry funding, and short term debt, totally hand to mouth.
In that time, a number of urgent crisis were encountered, which required immediate cash and so my wife provided private funding and this was supposed to have been paid back at the next placing of £750,000, which ended up being a Placing of £170,000 and subscription of £180,000, plus a rolling flexible facility from Cellulac. Debts to Cellulac were also supposed to be addressed from the Placing. However, shares were issued instead and Cellulac dealt with the debt to my wife with shares which was later paid back to Cellulac as advances made in the Loan Note (see RNS of the 1st November 2018).
So, Integumen did not issue shares to my wife, part of the payment of shares to Cellulac, was used to settle that small (£12,600) debt to my wife. That is why it was not shown up as a direct issue from Integumen.
On the second part, my wife, had not invested in MWG and did not gain 500% profit, like others, so she wished to participate in the Microsaic transformation, and used those shares to settle payment of £50,000 (plus her CGT on the profit from those shares).
I doubt if any single director of an AIM Company would be as open as that, and I don't begrudge her making a profit from helping to save Integumen (Deepverge) when nobody else would.
Dear StuoftheToon and your Mum
First, I am honoured to read of your interest in DeepVerge and while the investor side covers mostly the share price, there is both a personal side to investors and almost 50 team members involved behind the scenes, making a difference.
They and I look forward to ensuring that your Mum's investment and your inheritance continues to grow for a long time. I do, as you know, read the comments too and respond the best I can within the limits imposed by the conditions of AIM Rules, but hope that I provide enough to highlight the excitement and passion behind the "front man" as its the band that makes the magic while the front man merely delivers.
All the best to your Mum
Gerry
@Chesh, actually, be careful what you wish for. Beam me up Scotty and watch this space
@Chesh expanding as quickly as we can. I know what you meant :) The situation is such that it initially was to be a development cost project to give us an edge on working with the virus on real-world environment skin, but many existing clients we spoke to immediately requested that we test their products and ingredients for them on the virus with Labskin and it became a service offered to paying clients rather than a not-for-profit demonstration of Labskin. Everyone wins.
@Chesh/Glebe/dflynch Labskin initiated the CL3 laboratory to investigate a range of products and ingredients on skin specifically grown for that purpose in normal and soft oral cavity tissue. The original purpose was to identify and demonstrate for clients but we quickly were inundated with clients seeking to have their ingredients and products tested on the virus, so now it became a revenue generating service and it is up to clients to publish the findings or make claims based on the reports we provided them on their products. While we are not at liberty to mention products or clients under NDA, it is well documented that Unilever are working a range of tests over the next few years on Labskin in Liverpool University CL3 labs.
@Chesh... Yes we do
@GarryParry Skin microbiota is a combination of genetics, lifestyles and pollution. The multiple swabs taken for tests are for the purpose of being informed of the changes on the multi-layers of inner and outer skin and the impact of a range of ingredients used for specific times of the month, season and underlying health conditions.
@GarryParry
Modern Water Monitoring division has been in business for more than 30 years. It has sold and installed units in more than 60 countries (RNS below) It is not possible to release such information without verification. Units ordered are always sold in single units as can be seen from orders for equipment. For instance, 2020 was a slow year and China alone purchased 30 units of CTM and OVA
RNS 28 April refers to 60 counties https://uk.advfn.com/stock-market/london/modern-water-MWG/share-news/Modern-Water-PLC-AGM-Statement/77255223.
@DaveC55 We will indeed, once they are launched.
@Chesh it makes no sense that anyone who is in a 3 year share option program, which is tax efficient would want to quickly offload on a 10%, even 50% uplift. They have to buy them first at 30p and then sell them, so the value to them is better long term. But employees are not rushing to sell their shares here or slightly above for such a small gain.
@Glebewhite. That is correct. Employee warrants are time sensitive and are there both to incentivise and keep staff as they lose them if they leave the company.
@Chesh the two large deals relate to a) EU and China projects on converting early in-vivo animal studies to Labskin as a standard alternative for pharmaceutical pre-clinical studies and b) multiple large tenders for China provinces for their water monitoring which are all tender/bid projects.
Modern Water are already in 5 of the 23 Chinese Provinces and have 24 distributors around China currently serving that market
@Can be done, but requires pharmaceuticals
It will be a subscription service over a year as it recommends best daily skin regimen taking into account climate, environment, data from Fitbit-type worn health devices, as well as seasonal, female cycle hormonal alterations. Even suggesting minor changes to the daily regimen during that time based on microbiome balance calculations from algorithm derived from DNA Microbiota samples taken remotely 4 times a year. It is the most comprehensive long term personaised skincare subscription service that men and women, once they try it, can't resist having it as part of their healthy lifestyle